GLP-1 launches inject over 2x rise in India's weight-loss market sales in '25

Mounjaro tops revenue charts, recording ₹601 cr in sales within 9 months of launch

- SANKET KOUL

India’s anti-obesity market saw a significant growth in 2025 with sales surging 115 per cent on year, as new launches in the injectable glucagon-like peptide-1 (GLP-1) agonist space, such as tirzepatide and semaglutide, flew off the shelves.

Sales in the weight loss market soared to ₹1,230 crore in 2025, against ₹571 crore in 2024.

GLP-1 agonists are a class of medications that help regulate blood sugar, increase fullness (satiety), and slow stomach emptying, leading to weight loss and improved glucose control for type 2 diabetes and obesity. Among them, Eli Lilly’s Mounjaro (tirzepatide) topped the revenue charts, recording ₹601 crore in sales within nine months of its launch in March 2025, while Novo Nordisk’s Wegovy (semaglutide) saw overall sales of ₹61 crore in six months.

On the other hand, Ozempic, launched only last month in India has raked in ₹1 crore.